CellCentric

CellCentric

Private
Cambridge, EnglandHealthcare & Life Scienceshttps://www.cellcentric.com

Last Round

Series D

5/6/2026

Total Funding Raised

$476.7M

Momentum Score

25 /100

Company Overview

CellCentric is a biotechnology company specializing in clinical-stage cancer therapies that develop innovative small-molecule inhibitors targeting specific cancers, including relapsed refractory multiple myeloma.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

inobrodibp300/CBP inhibitormultiple myelomaoral oncology drugsmall molecule inhibitorcancer therapeuticsclinical-stage biotechblood cancerhematological malignanciesprostate cancercombination therapyfirst-in-class therapeuticepigeneticsMYC targetingIRF4 targetingdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CellCentric Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

CellCentric Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series D5/6/2026
Series C5/19/2025
Series C7/24/2024
Convertible Debt7/11/2023
Series C1/26/2022
Early Funding
10/22/2020

Key People

Founding team and executive leadership

Will West

CEO

Executive Team

Debbie Haynes

Chief Operating Officer

Executive Team

CellCentric Investors

Notable investors and investment history

InvestorRounds
UK Innovation & Science Seed FundEarly Funding
Forbion Capital PartnersSeries C
RA Capital ManagementSeries D, Series C
Future Planet Capital RegionalGrant
ForbionSeries D, Series C
BrightEdgeSeries C
Morningside VenturesSeries C, Series B, Early Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 6, 2026

    $220M round led by Venrock.

  • Dec 19, 2025

    Inobrodib enters Phase 3 trial for multiple myeloma and other cancers.

CellCentric Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CellCentric Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CellCentric's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, England
Employee Range52
Year Founded2003
Last Funding5/6/2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.